Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (91-100 of 221) with videos related to

Pageof 23
Sort By:
Cancer|October 13, 2007
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trialSylvie Negrier, David Perol, Alain Ravaud, et al.
Acta Oncologica (Stockholm, Sweden)|January 18, 2020
Prognostic factors for cancer patient admitted to a medical intensive care unitCamille Baylot, Adrienne Francopoulo, Marine Gross-Goupil, et al.
BMC Cancer|December 5, 2019
Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experienceAlexis Gonnet, Laura Salabert, Guilhem Roubaud, et al.
World Journal of Urology|February 16, 2005
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'ImmunothérapieSylvie Negrier, Frédéric Gomez, Jean-Yves Douillard, et al.
Bulletin Du Cancer|August 12, 2017
[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts]Pauline Bertolaso, Laura Leroy, Marine Gross-Goupil, et al.
European Urology|January 20, 2009
Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinomaGrégoire Robert, Grégoire Gabbay, Raphaël Bram, et al.
Urologic Oncology|November 17, 2009
Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathwaysHervé Wallerand, Jean-Christophe Bernhard, Stéphane Culine, et al.
Acta Oncologica (Stockholm, Sweden)|September 22, 2021
The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumoursLaura Haik, Aurore Gonthier, Amandine Quivy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalBernard Escudier, Joaquim Bellmunt, Sylvie Négrier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC studyAlain Ravaud, Thomas Cerny, Catherine Terret, et al.
Pageof 23

Showing results (91-100 of 221) with videos related to

Sort By:
Pageof 23
Cancer|October 13, 2007
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trialSylvie Negrier, David Perol, Alain Ravaud, et al.
Acta Oncologica (Stockholm, Sweden)|January 18, 2020
Prognostic factors for cancer patient admitted to a medical intensive care unitCamille Baylot, Adrienne Francopoulo, Marine Gross-Goupil, et al.
BMC Cancer|December 5, 2019
Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experienceAlexis Gonnet, Laura Salabert, Guilhem Roubaud, et al.
World Journal of Urology|February 16, 2005
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'ImmunothérapieSylvie Negrier, Frédéric Gomez, Jean-Yves Douillard, et al.
Bulletin Du Cancer|August 12, 2017
[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts]Pauline Bertolaso, Laura Leroy, Marine Gross-Goupil, et al.
European Urology|January 20, 2009
Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinomaGrégoire Robert, Grégoire Gabbay, Raphaël Bram, et al.
Urologic Oncology|November 17, 2009
Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathwaysHervé Wallerand, Jean-Christophe Bernhard, Stéphane Culine, et al.
Acta Oncologica (Stockholm, Sweden)|September 22, 2021
The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumoursLaura Haik, Aurore Gonthier, Amandine Quivy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalBernard Escudier, Joaquim Bellmunt, Sylvie Négrier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC studyAlain Ravaud, Thomas Cerny, Catherine Terret, et al.
Pageof 23